Clinical DevelopmentGenmab has committed to initiating a Phase III study for Rina-S in second-line plus endometrial cancer, demonstrating a strong commitment to advancing their treatment options.
Clinical PerformanceRina-S continues to show impressive efficacy in endometrial cancer with a confirmed objective response rate of 47–50% and encouraging early signs of durability.
Market PotentialThe blockbuster potential of Rina-S is bolstered by continued clinical success, serving as a key driver for potential upside in Genmab stock.